TRIB Trinity Biotech PLC ADS

Trinity Biotech plc to Host Investor Call

Trinity Biotech plc to Host Investor Call

Conference Call Scheduled for Wednesday, January 31, 2024 at 8:30 AM ET

DUBLIN, Ireland, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will host an investor call on Wednesday, January 31 at 8:30 AM ET to provide an update on business operations.

Conference Call Dial-In & Webcast Information

Date:Wednesday, January 31, 2024
Time:8:30 AM ET
United States:1-877-407-0784
International:1-201-689-8560
Conference ID:13744109
Webcast: for Webcast
CallMe™: for CallMe Feature



About Trinity Biotech


Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: .



Contact:Trinity Biotech plc

Des Fitzgerald

(353)-1-2769800
LifeSci Partners, LLC

Eric Ribner

(1)-646-751-4363

E-mail



EN
30/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Trinity Biotech PLC ADS

 PRESS RELEASE

Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redes...

Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for the company’s next-generation CGM+ biosensor platform DUBLIN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling positive clinical trial results demonstrating a major technical breakthrough and de-ris...

 PRESS RELEASE

Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing S...

Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient outcomes DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of a new testing service for preeclampsia, a significant advancem...

 PRESS RELEASE

Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260...

Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market WILSONVILLE, Ore. and DUBLIN, July 24, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today unveiled its new flagship product, CGM+, a next-generation wearable biosensor platform designed for the $260 billion AI wearables market. Now in the later stages of device development, CGM+ is Trinity’s new AI-native continuous glucose monitoring (CGM) sy...

 PRESS RELEASE

Trinity Biotech Reaches Profitability Inflection Point, Marking Major ...

Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround -Trinity Biotech projects it reached Adjusted EBITDA1 -positive operations during Q2 2025 and expects to be Adjusted EBITDA1 positive going forward, reflecting continued strong execution on its comprehensive transformation plan.- - The Company now expects to be meaningfully Adjusted EBITDA1 -positive and cashflow positive from ongoing operating activities, starting Q3 2025 and into the foreseeable future.- DUBLIN, July 01, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB...

 PRESS RELEASE

Trinity Biotech Secures Key Regulatory Approval for Offshored and Outs...

Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability Transition to Outsourced Production Reduces Fixed Costs and Supports Trinity’s Broader Profitability and Growth Objectives DUBLIN, June 24, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and dia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch